Abstract
Hepatitis B virus (HBV) infection is a well-established risk factor for hepatocellular carcinoma, but its role in extrahepatic cancers remains a subject of investigation. This study explores the association between HBV infection and gastric cancer (GC) risk, specifically examining the additive interaction between HBV and tobacco smoking in a Chinese population. The findings indicate that HBV infection significantly increases GC risk and acts synergistically with smoking to further elevate this risk.
Introduction
Gastric cancer (GC) is a leading cause of cancer mortality worldwide. While Helicobacter pylori is the primary known risk factor, it does not account for all cases, prompting researchers to investigate other potential contributors. Hepatitis B Virus (HBV), known for its ability to integrate into host DNA and induce chronic inflammation, has been suspected of playing a role in extrahepatic malignancies. However, previous studies on the HBV-GC link have yielded inconsistent results. This research clarifies this association within a high-risk Chinese population and investigates whether HBV interacts synergistically with common lifestyle factors like smoking and alcohol consumption.
Methods
The researchers conducted a hospital-based case-control study in Fujian Province, China, involving 409 patients with pathologically confirmed gastric cancer and 1,275 healthy controls recruited between 2019 and 2023.
Data Collection and Analysis
- Biomarker Testing: Serum Hepatitis B surface antigen (HBsAg) served as the primary marker for HBV infection.
- Statistical Modeling: Unconditional logistic regression was employed to calculate Odds Ratios (OR), adjusting for age, sex, BMI, and education.
- Interaction Analysis: The study focused on additive interaction, utilizing three metrics: Relative Excess Risk of Interaction (RERI), Attributable Proportion of Interaction (API), and the Synergy Index (S).
- Meta-analysis: To contextualize their findings, the researchers performed a meta-analysis, integrating their results with existing literature to provide a pooled estimate of the HBV-GC association.
Results
HBV Infection and Gastric Cancer Risk
The primary study found that HBV-positive individuals had a 3.30 times higher risk (OR = 3.30, 95% CI: 1.84–5.91) of developing gastric cancer compared to HBV-negative individuals after adjusting for confounders. This finding was supported by a broader meta-analysis of 17 studies, which yielded a pooled OR of 1.34 (95% CI: 1.19–1.50), confirming a consistent positive association across different populations.
Subgroup analyses further detailed the risk across demographics. For instance, the association was particularly pronounced in females (OR = 7.40) and older age groups (OR = 5.76 for those ≥60 years), although the interaction tests for sex and age did not reach statistical significance (p > 0.05).
Synergistic Interaction with Smoking
A key insight of this research is the "super-additive" effect between HBV and tobacco smoking. While both are independent risk factors, their combination significantly multiplies the risk:
- HBV-negative smokers: 2.00x risk.
- HBV-positive non-smokers: 4.27x risk.
- HBV-positive smokers: 4.73x risk.
The Synergy Index (S) was calculated at 5.45, indicating that the combined effect is nearly 5.5 times higher than the sum of individual risks. Furthermore, the Attributable Proportion of Interaction (API) was 0.78, suggesting that 78% of the cancer risk in HBV-positive smokers is specifically due to the interaction between these two factors. Interestingly, no such synergistic interaction was found between HBV infection and alcohol consumption.
Discussion
The study reinforces the growing consensus that HBV is an extrahepatic threat. The virus can be detected in gastric tissues, where it likely promotes oncogenesis through DNA integration and chronic oxidative stress. The identification of an additive interaction between HBV and smoking is crucial for public health, as it highlights a specific high-risk group where intervention could prevent a significant number of cancer cases.
Limitations
Several limitations should be noted. First, the study did not account for Helicobacter pylori infection, the primary driver of GC. Second, the hospital-based design may not perfectly represent the general population. Third, the use of HBsAg as a binary marker precludes analysis of HBV-DNA viral loads. Finally, as a case-control study, it demonstrates association rather than definitive causation; longitudinal cohort studies are required to confirm these findings.
Conclusion
HBV infection is significantly associated with an increased risk of gastric cancer, and this risk is dramatically amplified in individuals who smoke. These findings suggest that HBV screening and smoking cessation programs should be integrated into gastric cancer prevention strategies, particularly in high-prevalence regions.
Summary updated